HYDRALYTE_1170x120

Lupin Pharmaceuticals

Lupin gets FDA approval for budesonide inhalation suspension

Lupin gets FDA approval for budesonide inhalation suspension

MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced that it has received approval for its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules from the United States Food and Drug Administration to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. Lupin’s budesonide inhalation suspension, 0.5

Lupin gets FDA approval for generic Xenazine tablets

Lupin gets FDA approval for generic Xenazine tablets

MUMBAI, BALTIMORE — Lupin announced today that it has received final approval for its Tetrabenazine tablets, 12.5 mg and 25 mg from the United States Food and Drug Administration (FDA) to market a generic version of Valeant Pharmaceuticals North America’s  Xenazine tablets, 12.5 mg and 25 mg. These are used for the treatment of chorea associated

Lupin cleared to market generic Tamiflu suspension

Lupin cleared to market generic Tamiflu suspension

BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has received Food and Drug Administration approval for oseltamivir phosphate oral suspension 6 mg (base)/ml, a flu medication. Lupin said its oseltamivir oral suspension product, set to roll out soon, is a generic version of Tamiflu oral suspension (6 mg/ml) from Hoffman-La Roche Inc. Oseltamivir phosphate oral suspension is indicated

Lupin InspiraChamber gets preferred status at Albertsons

Lupin InspiraChamber gets preferred status at Albertsons

BALTIMORE — Food and drug retailer Albertsons Cos. has agreed to exclusively provide Lupin Pharmaceuticals Inc.’s InspiraChamber device to asthma and other respiratory patients in its stores. Lupin said Wednesday that Albertsons will offer the InspiraChamber, a valved holding chamber for the enhanced delivery of inhaled aerosol therapies, to patients in its more than 1,700

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly

Lupin releases Intermezzo generic in U.S.

Lupin releases Intermezzo generic in U.S.

BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has launched the first product from its Gavis pipeline, zolpidem sublingual tablets 1.75 mg and 3.5 mg, an insomnia drug. Lupin said its product is a generic version of Intermezzo sublingual tablets (1.75 mg and 3.5 mg) from Purdue Pharma. The Lupin generic received

Aurobindo launches generic of Suprax

DAYTON, N.J. — Aurobindo Pharma Ltd. has received the first Abbreviated New Drug Application approval from the Food and Drug Administration for cefixime for oral suspension, USP, 100 mg/5 ml and 200 mg/5 ml. Cefixime for O.S. is bioequivalent and therapeutically equivalent to Suprax from Lupin Pharmaceuticals Inc. It is indicated for the treatment of